主页 > 医学前沿 >
【文摘发布】《新英格兰》攻击肿瘤血管的新武
The approval by the Food and Drug Administration of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF),1 sparked enormous excitement among oncologists. Bevacizumab, the first cancer therapy that acts by blocking angiogenesis, is the result of the successful translation of pioneering work by the late Judah Folkman and his colleagues, who proposed that vascularization is essential for the growth of clinically relevant invasive carcinomas. A recent study by Fischer and colleagues2 indicates that a monoclonal antibody against another angiogenic protein, placental growth factor (PlGF), may also be a useful antiangiogenic therapy for cancer in humans.
http://intl-content.nejm.org/cgi/content/full/358/19/2066 NEJM的这个评论出的也太迟了点。
这个评论基于的研究论文（比利时的国宝级血管生成理论大师Carmeliet对PlGF——一个VEGF家族的成员——在肿瘤血管生成特殊地位的全面总结）发表在去年11月的Cell上，当时Cell同期就除了评论，作者是麻省总院的Jain（主要贡献在于“血管正常化（vascular normalization）”理论），去年11月的Nature Rev. Cancer上也有评论。
据说去年12月我们的新闻联播上面也报道了这个发现。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-11 17:11
医学,生命科学网